Ignite Creation Date:
2024-05-06 @ 4:00 PM
Last Modification Date:
2024-10-26 @ 2:01 PM
Study NCT ID:
NCT04835584
Status:
RECRUITING
Last Update Posted:
2022-03-21
First Post:
2021-04-05
Brief Title:
KRT-232 and TKI Study in Chronic Myeloid Leukemia
Sponsor:
Kartos Therapeutics Inc
Organization:
Kartos Therapeutics Inc
Study Overview
Official Title:
An Open-Label Multicenter Phase 1b2 Study of the Safety and Efficacy of KRT-232 Combined With a Tyrosine Kinase Inhibitor TKI in Patients With Relapsed or Refractory Ph Chronic Myeloid Leukemia CML
Status:
RECRUITING
Status Verified Date:
2022-03
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This study evaluates KRT-232 a novel oral small molecule inhibitor of MDM2 for the treatment of patients with Ph Chronic Myeloid Leukemia CML who have relapsed or are refractory or intolerant to a Tyrosine Kinase Inhibitor TKI
This study is a global open label Phase 1b2 to determine the efficacy and safety of KRT-232 in patients with chronic phase CML CML-CP and accelerated phase CML-AP who have failed TKI treatments
This study is a global open label Phase 1b2 to determine the efficacy and safety of KRT-232 in patients with chronic phase CML CML-CP and accelerated phase CML-AP who have failed TKI treatments
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None